Abzyme Therapeutics' pH-Dependent Anti-CD3 Antibody Secures Key Patent
LIMERICK, Pa .— Abzyme Therapeutics LLC, a Rockland-affiliated biotechnology company, has reached a significant milestone in its pursuit to develop innovative antibody-based therapies. Today, the company announced the award of U.S. Patent No. 12,116,411 for its groundbreaking anti-CD3 antibody technology. This patent solidifies Abzyme's intellectual property position and underscores its commitment to advancing novel cancer treatments.
Abzyme's patented antibodies exhibit a novel pH-dependent binding profile, demonstrating high affinity to human CD3 T-cell co-receptor within the acidic pH conditions found in solid tumors. This specificity minimizes off-tumor binding to normal tissues, a major challenge in antibody-based therapies. By leveraging the acidic tumor microenvironment, Abzyme's antibodies improve tumor targeting and reduce on-target off-tumor toxicity.
"We are thrilled to secure this important patent, which validates our innovative approach to antibody design," said Dr. Tran, CEO and co-founder of Abzyme Therapeutics. "These antibodies represent a significant step forward in developing more effective and targeted therapies for cancer patients."
The pH-dependent CD3 antibodies are evidence of Abzyme's pivotal platform, which allows for the engineering of conditionally-active antibodies with potential applications in various therapeutic areas, including:
- Antibody-drug conjugates (ADCs): Delivering potent cytotoxic payloads directly to tumor cells.
- T-cell engaging immunotherapies (TEIs): Recruiting patient's immune cells to attack cancer cells.
- Chimeric antigen receptor (CAR) T-cell therapy: Engineering patient's T cells to recognize and destroy tumor cells.
"This breakthrough has the potential to transform cancer treatment, addressing a critical unmet need for more targeted and effective therapies," commented Dr. Chimento, Vice President of Rockland. "We are grateful for the opportunity to support Abzyme in this remarkable achievement. Our collaboration in antibody discovery, protein engineering, and recombinant antibodies reflects our shared commitment to advancing the development and delivery of therapies worldwide."
About Abzyme Therapeutics
Abzyme Therapeutics is a biotechnology company dedicated to discovering and developing novel antibody-based therapies for a range of diseases. The company's focus is on creating innovative solutions to address unmet medical needs and improve patient outcomes.
About Rockland Immunochemicals, Inc.
Established in 1962, Rockland is a global biotechnology company manufacturing leading-edge tools for basic, applied, and clinical research for academic, biopharma, diagnostic, and agbio industries. Rockland is a privately held company, operating facilities with antibody and protein production capabilities near Philadelphia, Pennsylvania, USA. Learn more about Rockland at www.rockland.com.